Albinism, Oculocutaneous
Welcome,         Profile    Billing    Logout  
 8 Companies   6 Products   6 Products   13 Mechanisms of Action   0 Trials   16 News 
  • ||||||||||  Orfadin (nitisinone) / Astellas, SOBI
    Trial primary completion date:  Nitisinone for Type 1B Oculocutaneous Albinism (clinicaltrials.gov) -  Jan 31, 2017   
    P1/2,  N=5, Active, not recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: Dec 2017 --> Jul 2016
  • ||||||||||  Orfadin (nitisinone) / Astellas, SOBI
    Enrollment closed, Enrollment change, Trial primary completion date:  Nitisinone for Type 1B Oculocutaneous Albinism (clinicaltrials.gov) -  Sep 16, 2016   
    P1/2,  N=5, Active, not recruiting, 
    Trial primary completion date: Dec 2017 --> Jul 2016 Recruiting --> Active, not recruiting | N=50 --> 5 | Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Orfadin (nitisinone) / Astellas, SOBI
    Trial primary completion date:  Nitisinone for Type 1B Oculocutaneous Albinism (clinicaltrials.gov) -  Oct 8, 2015   
    P1/2,  N=50, Recruiting, 
    Recruiting --> Active, not recruiting | N=50 --> 5 | Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2015 --> Dec 2016
  • ||||||||||  Orfadin (nitisinone) / Astellas, SOBI
    Enrollment open:  Nitisinone for Type 1B Oculocutaneous Albinism (clinicaltrials.gov) -  Feb 18, 2014   
    P1/2,  N=8, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / AbbVie
    Trial withdrawal:  Medical Treatment of Colitis in Patients With Hermansky-Pudlak Syndrome (clinicaltrials.gov) -  Jan 24, 2013   
    P2,  N=0, Withdrawn, 
    Not yet recruiting --> Recruiting Terminated --> Withdrawn